GTBP Stock Based Compensation To Revenue from 2010 to 2025
| GTBP Stock | USD 2.34 0.12 4.88% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 125.37 | Current Value 131.64 | Quarterly Volatility 61.02599247 |
Check GT Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GT Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.4 M, Interest Expense of 232.7 K or Selling General Administrative of 8.8 M, as well as many indicators such as Price To Sales Ratio of 2.3 K, Dividend Yield of 0.0 or Days Sales Outstanding of 54.84. GTBP financial statements analysis is a perfect complement when working with GT Biopharma Valuation or Volatility modules.
GTBP | Stock Based Compensation To Revenue |
Latest GT Biopharma's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of GT Biopharma over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. GT Biopharma's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GT Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
GTBP Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 98.05 | |
| Geometric Mean | 32.72 | |
| Coefficient Of Variation | 62.24 | |
| Mean Deviation | 54.02 | |
| Median | 139.30 | |
| Standard Deviation | 61.03 | |
| Sample Variance | 3,724 | |
| Range | 139 | |
| R-Value | 0.79 | |
| Mean Square Error | 1,507 | |
| R-Squared | 0.62 | |
| Significance | 0.0003 | |
| Slope | 10.11 | |
| Total Sum of Squares | 55,863 |
GTBP Stock Based Compensation To Revenue History
About GT Biopharma Financial Statements
GT Biopharma shareholders use historical fundamental indicators, such as Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although GT Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in GT Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on GT Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 125.37 | 131.64 |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
| 0.64 | OPT | Opthea Earnings Call Today | PairCorr |
| 0.64 | LTRN | Lantern Pharma | PairCorr |
| 0.57 | PHGE | Biomx Inc | PairCorr |
| 0.48 | FENC | Fennec Pharmaceuticals | PairCorr |
| 0.47 | A | Agilent Technologies Earnings Call Today | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.